Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy

Objective: To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection. Data Sources: Literature was obtained through MEDLINE (1948-Novemb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Annals of pharmacotherapy 2012-02, Vol.46 (2), p.240-247
Hauptverfasser:	Spooner, Linda M, Olin, Jacqueline L
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological and medical sciences Dermatology Drug Costs Growth Hormone-Releasing Hormone - analogs & derivatives Growth Hormone-Releasing Hormone - economics Growth Hormone-Releasing Hormone - pharmacokinetics Growth Hormone-Releasing Hormone - therapeutic use HIV-Associated Lipodystrophy Syndrome - drug therapy HIV-Associated Lipodystrophy Syndrome - economics Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Medical sciences Off-Label Use Pharmacology. Drug treatments Skin involvement in other diseases. Miscellaneous. General aspects Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!